Risk Analysis of Intracranial Aneurysm Rupture Through Social Determinants of Health
NCT ID: NCT06866210
Last Updated: 2025-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1800 participants
OBSERVATIONAL
2024-10-15
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is therefore reasonable to study the interaction between rupture risk factors and SDOH on the rupture risk of IA. Several initiatives have been undertaken to assess rupture risk, but few have included SDH. Limitations were often raised, especially regarding data accessibility. However, it is now possible, thanks to artificial intelligence (AI) algorithms, particularly natural language processing (NLP), to reuse large-scale health data to address longstanding issues, such as those posed by SDH.
The use of health data warehouses (HDWs) offers an opportunity to collect and analyze accurate, real-world data, particularly through AI and NLP to extract information from medical reports. However, various challenges limit the use of NLP models, notably the dominance of models trained on English medical texts and privacy-related legislative restrictions. Therefore, alongside leveraging these models for clinical research, it is essential to continue efforts to develop transparent French-language models that comply with legislation.
Thus, the ARAMISS project proposes to study the interaction between SDH and known risk factors for IA rupture by comparing control populations and rupture cases. This study will be based on a certified health data warehouse (HDW) and an NLP algorithm previously developed by the team.
In parallel, the project plans two FAIR-compliant knowledge-sharing approaches to disseminate the algorithm and training corpus to the broader community.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hidden Impairments During Subarachnoid Haemorrhage Recovery, Description and Evolution of a Newly Described Syndrom
NCT06276517
Incidence, Characteristics and Evolution of Cerebral Vasospasm With Clinical Impact in Moderate to Severe Traumatic Brain Injury Complicated by Subarachnoid Hemorrhage at Martinique University Hospital
NCT06560372
Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage
NCT01779713
Searching a Dysfunction of Corticotropic & Thyrotropin Axis During the Acute Phase of a Subarachnoid Hemorrhage Secondary to Spontaneous Rupture of Cerebral Aneurysm
NCT03655509
Cerebral Autoregulation in Patients With Aneurysmal SubArachnoid Haemorrhage
NCT03987139
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One way to reduce this morbidity and societal burden is to identify patients at high risk of rupture to determine those most likely to experience disease progression. Various initiatives, such as the ELAPSS, PHASES, and UCAS scores, have been developed to assess rupture risk in routine clinical practice. However, these scores largely rely on well-known modifiable and non-modifiable risk factors, such as ethnicity, hypertension, sex, age, smoking, and history of subarachnoid hemorrhage. Despite their utility, they are insufficient for reliably stratifying rupture risk, underestimating it by approximately 30%, which limits their impact in daily practice.
Recent research has identified emerging risk and protective factors, such as sleep apnea syndrome, lipid control, and the use of antidiabetic, lipid-lowering, or antihypertensive treatments. Therefore, it is necessary to revisit IA rupture risk by considering these factors in relation to patients' living environments.
Social determinants of health (SDOH) play a critical role in this context. Defined as the conditions of life that influence individual and population health, SDOH include broad factors such as age, ethnicity, and gender, as well as addiction behaviors, income levels, environmental exposure, and social status. They are estimated to contribute to over 80% of the population's health outcomes. In vascular diseases, SDOH -such as low education levels, limited income, social isolation, and low physical activity-are known to impact disease severity beyond traditional risk factors. The WHO estimates that vascular diseases are the leading global cause of mortality, with 17.7 million deaths annually, half of which are preventable. Understanding and addressing SDOH is therefore crucial for public health prevention efforts.
Initial studies on the impact of SDOH on IA rupture are limited, often focusing on individual determinants. A more comprehensive approach to SDH is needed, especially given the lack of consensus guidelines for IA management. Current therapeutic options, while advanced, still carry perioperative morbidity. Multivariable modeling and weighted composite scores can help address the complexity of clinical and environmental factors.
SDH data are routinely collected in medical records and increasingly digitized through hospital information systems. Health data warehouses (HDWs), such as the one at Nantes University Hospital, integrate structured and unstructured data from millions of patients, enabling their reuse for research purposes. The advent of artificial intelligence (AI) has made it possible to extract and analyze this data, revealing insights from previously inaccessible information.
Natural language processing (NLP), a branch of AI, enables automated extraction of information from textual medical records, unlocking the potential of unstructured data within HDWs. State-of-the-art models, such as BERT, ChatGPT, Llama, and Mistral, can process and analyze large volumes of text. However, the application of NLP to non-English languages is constrained by a lack of annotated corpora, privacy concerns, and data sovereignty regulations.
The ARAMISS project aims to investigate the interaction between SDH and known risk factors for IA rupture, comparing patients with unruptured IAs to those with ruptured IAs. Using SDH, the project will classify patients into risk groups and spatially analyze patient data through APIs like DataGouv. Additionally, the project will focus on developing FAIR (Findable, Accessible, Interoperable, Reusable) methodologies to share its algorithms and training corpora with the biomedical community while maintaining regulatory compliance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ruptured IA or unruptured IA
ruptured IA or unruptured IA
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a confirmed saccular IA based on imaging;
* Presence of at least one document referencing social determinants of health, lifestyle, habits, or exposure.
Exclusion Criteria
* Patients diagnosed with dominant autosomal polycystic liver-kidney disease, sickle cell disease, mycotic aneurysm, fusiform aneurysm, blister-like aneurysm, Marfan syndrome, or Ehlers-Danlos syndrome.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nantes Hospital
Nantes, France, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAtAE-2023-5
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
RC24_0009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.